Want to see AU:GSS full AI Analyst Report?
Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.08
▼(-67.08% Downside)
Action:Upgraded
Date:08/26/26
The score is held down primarily by weak financial performance—deep negative margins, declining revenue, and multi-year negative operating/free cash flow—despite very low leverage. Technicals add some support from a short-term up-move (price above key short-term averages and positive MACD), but overbought readings and a weak longer-term trend temper that benefit. Valuation is also pressured by a negative P/E tied to ongoing losses, with no dividend yield provided.
Positive Factors
Proprietary Diagnostic Platform
Ownership of a proprietary molecular-diagnostics platform can support differentiated assay development, workflow integration and expansion into gastrointestinal, respiratory and other pathogen-testing markets.
Negative Factors
Declining Revenue
Persistent revenue contraction suggests weaker demand, customer adoption or commercial execution. Without a durable return to growth, fixed costs become harder to absorb and the platform’s market opportunity may not translate into scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Diagnostic Platform
Ownership of a proprietary molecular-diagnostics platform can support differentiated assay development, workflow integration and expansion into gastrointestinal, respiratory and other pathogen-testing markets.
Read all positive factors
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.76M
Dividend YieldN/A
Average Volume (3M)426.17K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-9.10%
EPS Growth31.75%
CountryAU
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.06
Shares Outstanding227,138,820
10 Day Avg. Volume870,477
30 Day Avg. Volume426,165
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.43
Price to Sales (P/S)1.05
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$21.80M
Genetic Signatures Ltd. Business Overview & Revenue Model
Company Description
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of ...
How the Company Makes Money
GSS makes money primarily by selling molecular diagnostic test products to clinical laboratories, hospitals, and reference labs, generating revenue from (1) consumable assay sales and (2) instrument- and workflow-related product sales where applic...
Genetic Signatures Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.45M | 15.90M | 9.77M | 16.94M | 35.42M |
| Gross Profit | -12.72M | 7.78M | 4.31M | -12.74M | 7.21M |
| EBITDA | -15.68M | -16.08M | -19.82M | -13.14M | 4.70M |
| Net Income | -14.01M | -20.10M | -17.86M | -14.05M | 3.06M |
Balance Sheet | |||||
| Total Assets | 38.46M | 54.63M | 67.29M | 49.08M | 59.65M |
| Cash, Cash Equivalents and Short-Term Investments | 22.09M | 31.30M | 36.25M | 16.35M | 36.90M |
| Total Debt | 310.00K | 791.00K | 1.22M | 0.00 | 34.00K |
| Total Liabilities | 2.73M | 4.54M | 6.18M | 6.16M | 4.85M |
| Stockholders Equity | 35.72M | 50.09M | 61.10M | 42.91M | 54.80M |
Cash Flow | |||||
| Free Cash Flow | -8.82M | -13.19M | -14.91M | -20.55M | 6.82M |
| Operating Cash Flow | -7.77M | -12.29M | -10.12M | -12.45M | 9.81M |
| Investing Cash Flow | 9.85M | -24.30M | -4.79M | -8.09M | -2.99M |
| Financing Cash Flow | -481.00K | 7.79M | 34.81M | -23.00K | -101.00K |
Genetic Signatures Ltd. Technical Analysis
Positive
0.24
Price Trends
0.07
Positive
0.08
Positive
0.12
Negative
Market Momentum
<0.01
Negative
64.80
Neutral
69.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.80 is Neutral, neither overbought nor oversold. The STOCH value of 69.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:GSS.
Genetic Signatures Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$512.93M | 22.25 | 15.80% | 4.73% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$19.76M | -1.41 | -35.10% | ― | -9.10% | 31.75% | |
47 Neutral | AU$39.44M | -1.59 | -75.96% | ― | -5.81% | -3.60% | |
45 Neutral | AU$31.67M | -4.92 | -205.17% | ― | 239.64% | -37.21% | |
43 Neutral | AU$25.44M | -3.43 | -881.94% | ― | 743.51% | -1.52% |
* Healthcare Sector Average
AU:GSS
Genetic Signatures Ltd.
0.09
-0.18
-67.78%
AU:BDX
BCAL Diagnostics Limited
0.07
<0.01
15.00%
AU:RHY
Rhythm Biosciences Ltd.
0.09
<0.01
2.35%
AU:ACL
Australian Clinical Labs Ltd
2.75
0.26
10.49%
AU:MAP
Microba Life Sciences Limited
0.06
-0.03
-38.89%
Genetic Signatures Ltd. Corporate Events
Genetic Signatures in Early Merger Talks With Microba to Build Infectious Disease Diagnostics Group
Aug 26, 2026
Genetic Signatures Ltd has entered preliminary talks with fellow ASX-listed group Microba Life Sciences over a potential merger aimed at creating a leading infectious disease diagnostics player. The proposed combination would unite Genetic Signatu...
Genetic Signatures Files ASX Corporate Governance Statement for 2026
Aug 25, 2026
Genetic Signatures Ltd has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with ASX requirements. The statement, approved by the board and accessible via the company’s website, outlines...
Genetic Signatures Tightens Losses and Restructures as Long-Term Deals Underpin Growth Plans
Aug 25, 2026
Genetic Signatures reported FY2026 revenue of $14.8 million, down 7% amid a competitive, price-sensitive market and a subdued respiratory testing season, but cut its net loss by 30% to $14.0 million and reduced operating cash outflows by 37% to $7...
Genetic Signatures Sets Date for FY2026 Results and Investor Briefing
Aug 24, 2026
Genetic Signatures Ltd., a global molecular diagnostics company, specialises in PCR-based EasyScreen assays built on its proprietary 3base platform to support high-volume hospitals and pathology laboratories in infectious disease screening. Its te...
Genetic Signatures Cuts Costs, Secures Danish Deal and Resets Global Growth Strategy
Jul 23, 2026
Genetic Signatures has completed an organisational restructuring that removes 30 roles, adds three project-focused positions and is expected to cut annual costs by about $5 million from FY2027, contributing to a leaner operating base. The move, to...
Genetic Signatures plays down BCAL stake, stresses business as usual
Jul 2, 2026
Genetic Signatures has responded to BCAL Diagnostics’ announcement that BCAL acquired shares in the company, clarifying it had no prior knowledge of the transaction and has received no communication about any strategic deal or corporate prop...
BCAL buys 10.2% stake in Genetic Signatures to broaden diagnostics platform
Jul 2, 2026
BCAL Diagnostics, an Australian healthcare company focused on early cancer detection, has taken a 10.2% stake in Genetic Signatures for $1.39 million in cash at $0.06 per share. Genetic Signatures’ infectious disease PCR platform and establi...
Genetic Signatures Outlines 90-Day Strategic Review Under Strict Investor Disclaimers
Jun 9, 2026
Genetic Signatures Ltd. has released an investor presentation outlining a 90-day strategic review designed to position the company for growth. The board-approved materials emphasise that the presentation is informational only and proprietary, rein...
Genetic Signatures Unveils Post-Review Strategy Ahead of Investor Webinar
Jun 8, 2026
Genetic Signatures will host an investor webinar on 10 June 2026 at 10:00am AEST, where CEO Maria Halasz will present findings from a 90-day review of the company’s operations, market position, product strategy and organisational structure. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.